THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA (AML)

Acute myeloid leukemia (AML) is a cancer of the myeloid line of white blood cells and is characterized by the hyperproliferation of abnormal cells, which collect in the bone marrow and disrupt normal blood cell production Replacement of normal bone marrow with leukemic cells causes a decrease in the levels of red blood cells, platelets and normal white blood cells Symptoms include fatigue, shortness of breath, a heightened risk of bruising and bleeding, and on elevated risk of infection Risk factors for AML have been identified, but the specific cause is still unknown Treatment generally involves chemotherapy and, in some cases, hematopoietic stem cell transplantation Treatment strategies for AML ore currently focusing on the discovery of new drug targets and prognostic indicators, as well as the detection of residual disease subsequent to treatment This article provides insight into the search for new and Improved treatment options by detailing the putative targets for drugs currently under active investigation for AML